148 related articles for article (PubMed ID: 37160416)
61. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
62. [A Case of Successful Treatment of Recurrent Peritoneal Dissemination of Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Combination Therapy].
Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Shinke G; Katsuyama S; Ikeshima R; Kawai K; Hiraki M; Sugimura K; Masuzawa T; Takeno A; Hata T; Murata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2027-2029. PubMed ID: 35045482
[TBL] [Abstract][Full Text] [Related]
63. Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.
Charonpongsuntorn C; Tanasanvimon S; Korphaisarn K; Payapwattanawong S; Siripoon T; Pakvisal N; Juengsamarn J; Phaibulvatanapong E; Chindaprasirt J; Prasongsook N; Udomdamrongkul K; Ngamphaiboon N; Sirachainan E
JCO Glob Oncol; 2022 Nov; 8():e2200205. PubMed ID: 36455172
[TBL] [Abstract][Full Text] [Related]
64. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
65. DYNLL1 is hypomethylated and upregulated in a tumor stage- and grade-dependent manner and associated with increased mortality in hepatocellular carcinoma.
Berkel C; Cacan E
Exp Mol Pathol; 2020 Dec; 117():104567. PubMed ID: 33171156
[TBL] [Abstract][Full Text] [Related]
66. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
Tomonari T; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Kawano Y; Okamoto K; Miyamoto H; Sato Y; Takayama T
Clin J Gastroenterol; 2023 Jun; 16(3):438-443. PubMed ID: 36856957
[TBL] [Abstract][Full Text] [Related]
67. Differentially expressed genes between early and advanced hepatocellular carcinoma (HCC) as a potential tool for selecting liver transplant recipients.
Mas VR; Maluf DG; Archer KJ; Yanek K; Williams B; Fisher RA
Mol Med; 2006; 12(4-6):97-104. PubMed ID: 16953559
[TBL] [Abstract][Full Text] [Related]
68. Long non-coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/β-catenin signalling pathway by targeting miR-320a.
Wu S; Chen S; Lin N; Yang J
J Cell Mol Med; 2020 Mar; 24(5):3108-3116. PubMed ID: 31970876
[TBL] [Abstract][Full Text] [Related]
69. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
70. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
[TBL] [Abstract][Full Text] [Related]
71. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
72. A Successful Case of Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab with Multisystem Immune-related Adverse Events.
Hayashi H; Sawada K; Hasebe T; Nakajima S; Sawada J; Takiyama Y; Takiyama Y; Okumura T; Fujiya M
Intern Med; 2022 Dec; 61(23):3497-3502. PubMed ID: 35491133
[TBL] [Abstract][Full Text] [Related]
73. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
74. KIF18B promotes hepatocellular carcinoma progression through activating Wnt/β-catenin-signaling pathway.
Yang B; Wang S; Xie H; Wang C; Gao X; Rong Y; Liu Z; Lu Y
J Cell Physiol; 2020 Oct; 235(10):6507-6514. PubMed ID: 32052444
[TBL] [Abstract][Full Text] [Related]
75. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
76. Methylation of the ataxia telangiectasia mutated gene (ATM) promoter as a radiotherapy outcome biomarker in patients with hepatocellular carcinoma.
Yan X; Wu T; Tang M; Chen D; Huang M; Zhou S; Zhang H; Yang X; Li G
Medicine (Baltimore); 2020 Jan; 99(4):e18823. PubMed ID: 31977876
[TBL] [Abstract][Full Text] [Related]
77. Advances in genomic hepatocellular carcinoma research.
Huang W; Skanderup AJ; Lee CG
Gigascience; 2018 Nov; 7(11):. PubMed ID: 30521023
[TBL] [Abstract][Full Text] [Related]
78. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia.
Suarez M I; Uribe D; Jaramillo CM; Osorio G; Perez JC; Lopez R; Hoyos S; Hainaut P; Pineau P; Navas MC
Ann Hepatol; 2015; 14(1):64-74. PubMed ID: 25536643
[TBL] [Abstract][Full Text] [Related]
79. Integrative molecular analysis of metastatic hepatocellular carcinoma.
Wang D; Zhu Y; Tang J; Lian Q; Luo G; Wen W; Zhang MQ; Wang H; Chen L; Gu J
BMC Med Genomics; 2019 Nov; 12(1):164. PubMed ID: 31722693
[TBL] [Abstract][Full Text] [Related]
80. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort.
Jost-Brinkmann F; Demir M; Wree A; Luedde T; Loosen SH; Müller T; Tacke F; Roderburg C; Mohr R
Aliment Pharmacol Ther; 2023 Jun; 57(11):1313-1325. PubMed ID: 36883351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
